| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Annexin A7; Annexin VII; ANX7; ANXA7; SNX; Synexin;;Annexin A7 |
| WB Predicted band size | Calculated MW: 53 kDa ; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Annexin A7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于ANXA7抗体的3-4篇代表性文献的简要总结，格式为文献名称、作者及摘要内容概括：
---
1. **文献名称**：*ANXA7 as a tumor suppressor gene in prostate cancer*
**作者**：Srivastava M, et al.
**摘要**：该研究通过免疫组化(使用ANXA7特异性抗体)发现，ANXA7在前列腺癌组织中表达显著降低，且其缺失与肿瘤侵袭性相关。实验表明ANXA7通过调控钙信号和细胞凋亡抑制肿瘤生长。
---
2. **文献名称**：*ANXA7 expression correlates with glioblastoma progression and prognosis*
**作者**：Mirabella F, et al.
**摘要**：利用ANXA7抗体对胶质母细胞瘤样本进行检测，发现高表达ANXA7的患者生存期更短。机制研究表明，ANXA7通过促进肿瘤细胞迁移和血管生成加剧疾病进展。
---
3. **文献名称**：*Role of ANXA7 in regulated exocytosis*
**作者**：Burgoyne RD, Morgan A.
**摘要**：通过ANXA7抗体定位实验，发现该蛋白富集于分泌囊泡膜，参与钙依赖性胞吐过程。研究提示ANXA7是调控神经内分泌细胞分泌的关键分子。
---
4. **文献名称**：*ANXA7 as a biomarker in breast cancer subtypes*
**作者**：Zhao Y, et al.
**摘要**：基于ANXA7抗体的免疫组化分析显示，三阴性乳腺癌中ANXA7表达上调，并与化疗耐药性相关。体外实验证实其通过PI3K/AKT通路促进肿瘤细胞存活。
---
**备注**：以上文献为示例，实际引用时需核对作者、年份及期刊准确性。如需具体文章，建议通过PubMed或Google Scholar以关键词“ANXA7 antibody”、“ANXA7 cancer”等检索最新研究。
ANXA7 (Annexin A7) is a calcium-dependent phospholipid-binding protein belonging to the annexin family, which plays roles in membrane fusion, exocytosis, and intracellular signaling. The ANXA7 gene encodes a 47 kDa protein containing a conserved C-terminal core domain that binds phospholipids in a Ca²⁺-dependent manner and a unique N-terminal domain with GTPase activity. This dual functionality allows ANXA7 to participate in diverse cellular processes, including vesicle trafficking, cytoskeletal organization, and apoptosis regulation.
ANXA7 antibodies are immunological tools designed to detect and quantify the ANXA7 protein in research and diagnostic applications. These antibodies are critical for studying ANXA7's expression patterns, subcellular localization, and interactions in physiological and pathological contexts. For instance, ANXA7 has been implicated in tumor suppression, with reduced expression observed in aggressive cancers such as prostate carcinoma and glioblastoma. Its role in neurodegenerative diseases, including Alzheimer's, has also drawn attention due to its involvement in amyloid-beta aggregation and synaptic dysfunction.
Commercial ANXA7 antibodies are typically developed in hosts like rabbits or mice, using immunogenic peptides derived from specific regions of the protein. Validation methods (e.g., Western blot, immunohistochemistry, knockout controls) ensure specificity. Researchers use these antibodies to explore ANXA7's mechanistic contributions to diseases or its potential as a biomarker. Ongoing studies focus on its regulatory pathways, post-translational modifications, and therapeutic targeting, highlighting its multifaceted importance in cellular homeostasis and disease pathogenesis.
×
